'Failed drug' could offer new approach to Epstein-Barr virus and resulting diseases

Researchers have found that the Epstein-Barr virus triggers infected cells to ramp up the production of an enzyme known as IDO1, a discovery that offers a promising starting point for putting the brakes on EBV. 

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE